



MEDIA RELEASE

22 June 2006

Cytopia Limited PO Box 6492
Level 5 St Kilda Road Central
Baker Heart Research Melbourne VIC 8008
Institute Building Australia
Commercial Road
Melbourne VIC 3004
Australia

Pooled Development Fund status

Cytopia Limited (ASX:CYT) today announced that it has been granted approval by the Pooled Development Funds (PDF) Registration Board to maintain its status as a registered PDF until 30 June 2007.

There are special taxation concessions available to both the company and its shareholders whilst Cytopia remains a PDF. For shareholders, profits derived from a sale of Cytopia shares, whether by way of capital gain or income, are exempt from Australian taxation.

Shareholders have previously given the board discretion to relinquish PDF registration if it were deemed incompatible with the growth plans of the company or the company was unable to meet the legislative requirements. Continuation of registration was recently sought as there was no commercial advantage to the company or its shareholders in relinquishing PDF status at this time. However, the company is unlikely to meet the legislative requirements of the PDF Act by 30 June 2007 and therefore no further extension of registration from the Registration Board is expected.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer, immune disorders and cardiovascular diseases. Cytopia conducts its research and development via subsidiaries based in Melbourne and New York and specialises in discovering new molecules that can inhibit enzymes known as kinases, an exciting new class of drugs.

For more information please contact either:

Mr Robert Watson
Executive Chairman

T: +61 3 9522 6900

E: bob.watson@cytopia.com.au

Mr. Andrew Macdonald
CEO

T: +61 3 9522 6920

E: andrew.macdonald@cytopia.com.au

or, visit our website at: www.cytopia.com.au